Last reviewed · How we verify
DA-001
DA-001 is a small molecule that targets the PI3K/AKT pathway.
DA-001 is a small molecule that targets the PI3K/AKT pathway. Used for Metastatic breast cancer, Metastatic colorectal cancer.
At a glance
| Generic name | DA-001 |
|---|---|
| Sponsor | Applied Biology, Inc. |
| Drug class | PI3K inhibitor |
| Target | PI3K |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
DA-001 works by inhibiting the PI3K/AKT pathway, which is involved in cell proliferation and survival. This inhibition leads to the reduction of tumor growth and metastasis. Additionally, DA-001 has been shown to have anti-angiogenic properties, further contributing to its anti-tumor effects.
Approved indications
- Metastatic breast cancer
- Metastatic colorectal cancer
Common side effects
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
- Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth (PHASE2, PHASE3)
- An Exploratory Clinical Study of UX-DA001 in Subjects With Idiopathic Parkinson's Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DA-001 CI brief — competitive landscape report
- DA-001 updates RSS · CI watch RSS
- Applied Biology, Inc. portfolio CI